Heron Therapeutics | HRTX - Operating Profit


Heron Therapeutics reported $38K in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
ALKERMES USD -48.28M 37.33M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Eisai JPY -10.31B 30.35B Mar/2026
Emergent BioSolutions USD -218M 69.9M Jun/2023
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 4.62M 1.43M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Veracyte USD 19.08M 5.55M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026